{"id":411946,"date":"2021-01-11T08:03:53","date_gmt":"2021-01-11T13:03:53","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411946"},"modified":"2021-01-11T08:03:53","modified_gmt":"2021-01-11T13:03:53","slug":"zymeworks-highlights-2020-achievements-and-announces-corporate-priorities","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/","title":{"rendered":"Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities<\/b><\/p>\n<p>VANCOUVER, British Columbia&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nZymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2020 and updated its corporate priorities.\n<\/p>\n<p>\n\u201c2020 was a leap forward for our lead clinical program in terms of a potential first approval and future approvals,\u201d said Ali Tehrani, Ph.D., President and CEO at Zymeworks. \u201cThe launch of our first pivotal trial and achievement of Breakthrough Therapy designation for zanidatamab mark important milestones towards our accelerated commercialization strategy, and our new clinical partnerships further strengthen zanidatamab\u2019s broad therapeutic profile. 2021 promises to be a data-rich year for both zanidatamab and ZW49 as we continue to demonstrate their potential to become foundational therapies in the treatment of HER2-expressing cancers.\u201d\n<\/p>\n<p><b><span class=\"bwuline\">2020 Achievements <\/span><\/b><\/p>\n<p><b><i>Zanidatamab Enters Late-Stage Clinical Development with Accelerated Strategy<\/i><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nZymeworks initiated a global pivotal trial (HERIZON-BTC-01) for zanidatamab monotherapy in patients with previously treated HER2 gene-amplified biliary tract cancer (BTC). This single arm trial is designed to support accelerated approval based on a primary endpoint of objective response rate and may enable submission of a Biologics License Application (BLA) as early as 2022.\n<\/li>\n<li>\nZanidatamab received additional drug review special designations in the U.S. and the European Union. The U.S. Food and Drug Administration (FDA) granted <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zymeworks.com%2FNews-Releases%2Fnews-details%2F2020%2FZymeworks-Receives-FDA-Breakthrough-Therapy-Designation-for-HER2-Targeted-Bispecific-Antibody-Zanidatamab-in-Patients-with-Biliary-Tract-Cancer%2Fdefault.aspx&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=Breakthrough+Therapy+designation&amp;index=1&amp;md5=17578881b3995088deeaf8d842630779\">Breakthrough Therapy designation<\/a> for BTC and the European Commission (EC) granted <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zymeworks.com%2FNews-Releases%2Fnews-details%2F2020%2FZymeworks-Receives-Orphan-Drug-Designation-From-the-European-Commission-for-HER2-Targeted-Bispecific-Antibody-Zanidatamab-in-Patients-With-Gastric-Cancer%2Fdefault.aspx&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=Orphan+Drug+designation&amp;index=2&amp;md5=22dd4505b482e8c93434d4e2ba8aac77\">Orphan Drug designation<\/a> for gastroesophageal adenocarcinoma (GEA), expediting potential commercialization. Previously the FDA granted two Fast Track designations to zanidatamab, in BTC and GEA, in addition to Orphan Drug designations for BTC, GEA, and ovarian cancer.\n<\/li>\n<\/ul>\n<p><b><i>Zanidatamab Data and Partnerships Continue to Support Broad Therapeutic Potential<\/i><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Gastric Cancer: <\/b>Clinical data from patients with refractory GEA treated with zanidatamab monotherapy as well as zanidatamab in combination with chemotherapy were updated and support plans to launch a second pivotal trial as 1<sup>st<\/sup> line treatment for advanced HER2-positive GEA in mid-2021 with partner BeiGene. These data will be updated as part of an <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zymeworks.com%2FNews-Releases%2Fnews-details%2F2020%2FZanidatamab-Clinical-Data-Selected-for-Oral-Presentation-at-the-American-Society-of-Clinical-Oncology-ASCO-Gastrointestinal-Cancers-Symposium%2Fdefault.aspx&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=oral+presentation&amp;index=3&amp;md5=56e2c00f9e0423949cbf08e41de019e9\">oral presentation<\/a> at the upcoming American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 15, 2021.\n<\/li>\n<li><b>Breast Cancer: <\/b>Clinical collaborations were initiated to evaluate zanidatamab in combination with a CD47 blocker (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zymeworks.com%2FNews-Releases%2Fnews-details%2F2020%2FZymeworks-and-ALX-Oncology-Announce-Clinical-Collaboration-Evaluating-Zanidatamab-with-the-CD47-Blocker-ALX148-in-Patients-with-Advanced-HER2Expressing-Breast-Cancer%2Fdefault.aspx&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=ALX+Oncology%26%238217%3Bs+ALX148&amp;index=4&amp;md5=4598bdd0f8529b855673b8f70b58b131\">ALX Oncology\u2019s ALX148<\/a>) in patients with advanced HER2\u2011expressing breast cancer and with a CDK4\/6 inhibitor<span class=\"bwuline\"> (<\/span><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zymeworks.com%2FNews-Releases%2Fnews-details%2F2020%2FZymeworks-Announces-Agreement-with-Pfizer-and-Initiation-of-a-New-Phase-2-Trial-Evaluating-ZW25-in-Combination-with-Ibrance-palbociclib%2Fdefault.aspx&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=Pfizer%26%238217%3Bs+Ibrance%29&amp;index=5&amp;md5=3e347a47d229e0cb0444644e374b6f79\">Pfizer\u2019s Ibrance)<\/a> in patients with HER2\u2011positive, HR-positive breast cancer.\n<\/li>\n<li><b>Endometrial Cancer:<\/b> Zymeworks\u2019 first investigator-led trial was initiated by Dr. Vicky Makker at Memorial Sloan Kettering Cancer Center. The Phase 2 trial will evaluate zanidatamab monotherapy in HER2-overexpressed advanced endometrial cancers and carcinosarcomas.\n<\/li>\n<\/ul>\n<p><b><i>Clinical Advancement of HER2 Bispecific ADC, ZW49, for HER2 Expressing Cancers<\/i><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nZW49 is being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved therapies, including HER2-targeted agents. Clinical studies continued in 2020 with dose escalation to determine the safety and efficacy profile of ZW49. Zymeworks will be providing a clinical progress update for ZW49 by <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zymeworks.com%2Fevents-and-presentations%2FEvents-and-Presentations%2Fdefault.aspx&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=webcast+on+Wednesday%2C+January+27%2C+2021+at+4%3A30+pm+ET&amp;index=6&amp;md5=90e440389f04128fbb421098b877455f\">webcast on Wednesday, January 27, 2021 at 4:30 pm ET<\/a>.\n<\/li>\n<\/ul>\n<p><b><i>Commercial, Clinical and Scientific Competencies Added to Leadership Team<\/i><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nZymeworks welcomed key commercial, scientific and clinical development talent to the leadership team with the additions of <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zymeworks.com%2Fabout%23guowei-fang&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=Guowei+Fang&amp;index=7&amp;md5=ae8c4963ea06854e7f67f8f7b6ee1422\">Guowei Fang<\/a>, Ph.D., as Senior Vice President, Research, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zymeworks.com%2Fabout%23james-priour&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=James+Priour&amp;index=8&amp;md5=0b05a78da7af184746b333d8650eae1b\">James Priour<\/a> as Senior Vice President, Commercial, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zymeworks.com%2Fabout%23manny-duenas&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=Manny+Duenas&amp;index=9&amp;md5=32f889c7e55fe2162aa9657de59ba861\">Manny Duenas<\/a> as Vice President, Global Value and Access, and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zymeworks.com%2Fabout%23pam-farmer&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=Pamela+Farmer&amp;index=10&amp;md5=a176b2ac3370cbd9de21336fc2902555\">Pamela Farmer<\/a>, MD, as Vice President, Global Patient Safety.\n<\/li>\n<\/ul>\n<p><b><i>Partnerships Advance: Milestone Payments Received and Deal Values Increase<\/i><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nOur partnerships continued to advance in 2020 with <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zymeworks.com%2FNews-Releases%2Fnews-details%2F2020%2FExelixis-In-Licenses-Iconic-Therapeutics-Tissue-Factor-Targeting-Antibody-Drug-Conjugate-Ahead-of-Planned-Investigational-New-Drug-Application%2Fdefault.aspx&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=Iconic%2FExelixis&amp;index=11&amp;md5=74a7a994ed92bc6c0abc0347b567bd2e\">Iconic\/Exelixis<\/a> achieving a milestone for ZymeLink\u2122 together with new and expanded Azymetric\u2122 and EFECT\u2122 collaborations with <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zymeworks.com%2FNews-Releases%2Fnews-details%2F2020%2FZymeworks-Announces-New-Multispecific-Antibody-Collaboration-with-Merck%2Fdefault.aspx&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=Merck&amp;index=12&amp;md5=b3812f7aa461bb9c0be96bfdccc7bf3c\">Merck<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zymeworks.com%2FNews-Releases%2Fnews-details%2F2020%2FZymeworks-Corporate-Update-Webcast-and-Conference-Call-Summary%2Fdefault.aspx&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=BMS&amp;index=13&amp;md5=6cb20a29d0df0c6075bcd21d16bf3a03\">BMS<\/a>. Zymeworks has nine active collaborations that could result in up to US$8.6 billion in potential milestone payments in addition to royalties on potential product sales.\n<\/li>\n<\/ul>\n<p><b><i>Balance Sheet Strengthened and Cash Runway Extended <\/i><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn early 2020, Zymeworks completed an <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zymeworks.com%2FNews-Releases%2Fnews-details%2F2020%2FZymeworks-Announces-Closing-of-Public-Offering-and-Exercise-in-Full-of-the-Underwriters-Over-Allotment-Option-to-Purchase-Additional-Shares%2Fdefault.aspx&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=oversubscribed+public+financing&amp;index=14&amp;md5=bbb94d69e39058d7f37e187ece43c8aa\">oversubscribed public financing<\/a> raising US$320.8 million, extending its runway into 2022 and potentially beyond. The Company also received non-dilutive capital from several of its pharmaceutical partners.\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">Updated Corporate Priorities <\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nComplete enrolment of zanidatamab pivotal trial in HER2+ biliary tract cancer\n<\/li>\n<li>\nLaunch pivotal trial in 1<sup>st<\/sup> line HER2+ GEA and present supporting Phase 2 clinical data\n<\/li>\n<li>\nPresent data to support zanidatamab breast cancer development strategy\n<\/li>\n<li>\nAdvance ZW49 into and complete cohort expansion\n<\/li>\n<li>\nPresent data from new therapeutic programs and technology platforms\n<\/li>\n<\/ul>\n<p><b>About Zymeworks Inc. <\/b><\/p>\n<p>\nZymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks\u2019 suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks\u2019 lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric\u2122 bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2+ biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2+ gastroesophageal and breast cancers. Zymeworks\u2019 second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks\u2019 proprietary ZymeLink\u2122 linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For additional information about Zymeworks, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.zymeworks.com&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=www.zymeworks.com&amp;index=15&amp;md5=8e37402772cd3d2a781a7ec9006fbef0\">www.zymeworks.com<\/a> and follow <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FZymeworksInc&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=%40ZymeworksInc&amp;index=16&amp;md5=0be369ad9f42635e8b78f025d710ef74\">@ZymeworksInc<\/a> on Twitter.\n<\/p>\n<p><b>Zymeworks Cautionary Note Regarding Zymeworks\u2019 Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release includes \u201cforward-looking statements\u201d within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and \u201cforward-looking information\u201d within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this news release include statements that relate to Zymeworks\u2019 global pivotal trial for zanidatamab in BTC (including the potential submission of a BLA), commercialization strategy, anticipated updates for zanidatamab and ZW49 and their potential to become foundational therapies in the treatment of HER2-expressing cancers, plans to launch a second pivotal trial with BeiGene, potential milestone payments and royalties on potential product sales, anticipated cash runway, and other information that is not historical information. When used herein, words such as \u201cmay\u201d, \u201cwill\u201d, \u201cplan\u201d, \u201ccontinue\u201d, \u201cpotential\u201d, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks\u2019 current expectations and various assumptions, including assumptions regarding anticipated reporting of additional clinical and preclinical data, the efficacy of ZW25, ZW49, and Zymeworks\u2019 therapeutic platforms, and Zymeworks\u2019 ability to enter into new partnership arrangements. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation, market conditions and the factors described under \u201cRisk Factors\u201d in Zymeworks\u2019 Quarterly Report on Form 10-Q for its fiscal quarter ended September 30, 2020 (a copy of which may be obtained at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=17&amp;md5=84362d35f442d60551c0e4bfc194c0e3\">www.sec.gov<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sedar.com%2F&amp;esheet=52359409&amp;newsitemid=20210111005427&amp;lan=en-US&amp;anchor=www.sedar.com&amp;index=18&amp;md5=c52bd26ce519488ed8be17f08cb578ec\">www.sedar.com<\/a>). Consequently, forward-looking statements should be regarded solely as Zymeworks\u2019 current plans, estimates, and beliefs. You should not place undue reliance on forward-looking statements. Zymeworks cannot guarantee future results, events, levels of activity, performance, or achievements. Zymeworks does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances, or to reflect the occurrences of unanticipated events, except as may be required by law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005427r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210111005427\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210111005427\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Inquiries:<br \/>\n<br \/>Ryan Dercho, Ph.D.<br \/>\n<br \/>(604) 678-1388<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@zymeworks.com\">ir@zymeworks.com<\/a><\/p>\n<p>\nTiffany Tolmie<br \/>\n<br \/>(604) 678-1388<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@zymeworks.com\">ir@zymeworks.com<\/a><\/p>\n<p>\nMedia Inquiries:<br \/>\n<br \/>Mary Klem<br \/>\n<br \/>(604) 678-1388<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@zymeworks.com\">media@zymeworks.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Clinical Trials Biotechnology Health Pharmaceutical General Health Other Science Science Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210111005427\/en\/183056\/3\/Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211; Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2020 and updated its corporate priorities. \u201c2020 was a leap forward for our lead clinical program in terms of a potential first approval and future approvals,\u201d said Ali Tehrani, Ph.D., President and CEO at Zymeworks. \u201cThe launch of our first pivotal trial and achievement of Breakthrough Therapy designation for zanidatamab mark important milestones towards our accelerated commercialization strategy, and our new clinical partnerships further strengthen zanidatamab\u2019s broad therapeutic profile. 2021 promises to be a data-rich year for both zanidatamab and ZW49 as we continue to demonstrate their potential to become foundational &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411946","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211; Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2020 and updated its corporate priorities. \u201c2020 was a leap forward for our lead clinical program in terms of a potential first approval and future approvals,\u201d said Ali Tehrani, Ph.D., President and CEO at Zymeworks. \u201cThe launch of our first pivotal trial and achievement of Breakthrough Therapy designation for zanidatamab mark important milestones towards our accelerated commercialization strategy, and our new clinical partnerships further strengthen zanidatamab\u2019s broad therapeutic profile. 2021 promises to be a data-rich year for both zanidatamab and ZW49 as we continue to demonstrate their potential to become foundational &hellip; Continue reading &quot;Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T13:03:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005427r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities\",\"datePublished\":\"2021-01-11T13:03:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\\\/\"},\"wordCount\":1309,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210111005427r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\\\/\",\"name\":\"Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210111005427r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-01-11T13:03:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210111005427r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210111005427r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/","og_locale":"en_US","og_type":"article","og_title":"Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities - Market Newsdesk","og_description":"Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211; Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2020 and updated its corporate priorities. \u201c2020 was a leap forward for our lead clinical program in terms of a potential first approval and future approvals,\u201d said Ali Tehrani, Ph.D., President and CEO at Zymeworks. \u201cThe launch of our first pivotal trial and achievement of Breakthrough Therapy designation for zanidatamab mark important milestones towards our accelerated commercialization strategy, and our new clinical partnerships further strengthen zanidatamab\u2019s broad therapeutic profile. 2021 promises to be a data-rich year for both zanidatamab and ZW49 as we continue to demonstrate their potential to become foundational &hellip; Continue reading \"Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T13:03:53+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005427r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities","datePublished":"2021-01-11T13:03:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/"},"wordCount":1309,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005427r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/","name":"Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005427r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-01-11T13:03:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005427r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005427r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411946"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411946\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}